122 related articles for article (PubMed ID: 11091779)
1. Impact of drug maintenance treatment on injection practices among French HIV-infected IDUs. The MANIF 2000 Study Group.
Reynaud-Maurupt C; Carrieri MP; Gastaud JA; Pradier C; Obadia Y; Moatti JP
AIDS Care; 2000 Aug; 12(4):461-70. PubMed ID: 11091779
[TBL] [Abstract][Full Text] [Related]
2. Profiles of self-reported HIV-risk behaviors among injection drug users in methadone maintenance treatment, detoxification, and needle exchange programs.
Mark HD; Nanda J; Davis-Vogel A; Navaline H; Scotti R; Wickrema R; Metzger D; Sochalski J
Public Health Nurs; 2006; 23(1):11-9. PubMed ID: 16460416
[TBL] [Abstract][Full Text] [Related]
3. A cross-sectional study on factors including HIV testing and counselling determining unsafe injecting practices among injecting drug users of Manipur.
Sarkar S; Panda S; Sarkar K; Hangzo CZ; Bijaya L; Singh NY; Das N; Agarwal A; Chatterjee A; Deb BC
Indian J Public Health; 1995; 39(3):86-92. PubMed ID: 8690497
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine injection in Melbourne, Australia--an update.
Aitken CK; Higgs PG; Hellard ME
Drug Alcohol Rev; 2008 Mar; 27(2):197-9. PubMed ID: 18264882
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
[TBL] [Abstract][Full Text] [Related]
6. [Risk reduction and intravenous drug use abstinence in patients with HIV infection. The SEROCO group].
Meyer L; Wade A; Persoz A; Boué F; Dellamonica P; Caroli-Bosc C; Carré N
Rev Epidemiol Sante Publique; 1998 Feb; 46(1):34-9. PubMed ID: 9533232
[TBL] [Abstract][Full Text] [Related]
7. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.
Emmanuelli J; Desenclos JC
Addiction; 2005 Nov; 100(11):1690-700. PubMed ID: 16277629
[TBL] [Abstract][Full Text] [Related]
8. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
[TBL] [Abstract][Full Text] [Related]
9. Injecting misuse of buprenorphine among French drug users.
Obadia Y; Perrin V; Feroni I; Vlahov D; Moatti JP
Addiction; 2001 Feb; 96(2):267-72. PubMed ID: 11182872
[TBL] [Abstract][Full Text] [Related]
10. Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy.
Avants SK; Margolin A; Usubiaga MH; Doebrick C
J Subst Abuse Treat; 2004 Mar; 26(2):67-78. PubMed ID: 15050083
[TBL] [Abstract][Full Text] [Related]
11. Safe sex? Misconceptions, gender differences and barriers among injection drug users: a focus group approach.
Weiss SH; Weston CB; Quirinale J
AIDS Educ Prev; 1993; 5(4):279-93. PubMed ID: 8297708
[TBL] [Abstract][Full Text] [Related]
12. The relative risk of HIV among IDUs not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
AIDS Care; 2009 Aug; 21(8):984-91. PubMed ID: 20024754
[TBL] [Abstract][Full Text] [Related]
13. A longitudinal investigation into excess risk for blood-borne infection among young injection drug users (IUDs).
Miller CL; Strathdee SA; Li K; Kerr T; Wood E
Am J Drug Alcohol Abuse; 2007; 33(4):527-36. PubMed ID: 17668338
[TBL] [Abstract][Full Text] [Related]
14. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group.
Carrieri MP; Vlahov D; Dellamonica P; Gallais H; Lepeu G; Spire B; Obadia Y
Drug Alcohol Depend; 2000 Jul; 60(1):51-4. PubMed ID: 10821989
[TBL] [Abstract][Full Text] [Related]
15. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
[TBL] [Abstract][Full Text] [Related]
16. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).
Spire B; Lucas GM; Carrieri MP
Int J Drug Policy; 2007 Aug; 18(4):262-70. PubMed ID: 17689374
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment.
Backmund M; Reimer J; Meyer K; Gerlach JT; Zachoval R
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S330-5. PubMed ID: 15768343
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver.
Kerr T; Marsh D; Li K; Montaner J; Wood E
Drug Alcohol Depend; 2005 Dec; 80(3):329-35. PubMed ID: 15964714
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with client-reported HIV infection among clients entering methadone treatment.
MacGowan RJ; Fichtner RR; Swanson N; Collier C; Kroliczak A; Cole G
AIDS Educ Prev; 1997 Jun; 9(3):205-17. PubMed ID: 9241388
[TBL] [Abstract][Full Text] [Related]
20. HIV infection as a predictor of methadone maintenance outcomes in Chinese injection drug users.
Zhao L; Holzemer WL; Johnson M; Tulsky JP; Rose CD
AIDS Care; 2012; 24(2):195-203. PubMed ID: 21780984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
